Sangram Nag

Sangram Nag is a distinguished researcher currently serving as the Team Leader of Radiochemistry Research &

With a focus on radiochemistry development and automation, Sangram specializes in working with short-lived isotopes like carbon-11 and fluorine-18. He has been pivotal in the development of over 125 radioligands labeled with short-lived isotopes, many of which have successfully transitioned for comprehensive biological evaluation using autoradiography and PET imaging in preclinical studies. Sangram's commitment to advancing PET radioligands aligns with both academic objectives and collaborative ventures with pharmaceutical industry partners.

Moreover, Sangram is deeply invested in the mentorship and guidance of PhD students, playing a significant role in nurturing emerging scientific talent. His scientific pursuits are centered on innovating novel PET radioligands, particularly those labeled with carbon-11 and fluorine-18, tailored for applications within the central nervous system. By envisioning translational imaging that seamlessly bridges the gap from animal models to clinical application in patients, Sangram's research efforts have led to the publication of 58 scientific papers encompassing radiochemistry and molecular imaging domains.

Through his dedication to advancing cutting-edge imaging technologies, Sangram aims to contribute significantly to the realm of precision diagnostics and therapeutics for central nervous system disorders, marking him as a notable figure in the field of PET radioligands and neuroscience research.

Research Interest of Sangram Nag:

The research focus of Sangram Nag lies at the intersection of neuroimaging and radiopharmaceutical development, particularly within the realm of Positron Emission Tomography (PET) for Central Nervous System (CNS) imaging. With a keen interest in advancing the field of PET radioligands, Sangram is dedicated to crafting novel radioligands tailored to target precise CNS receptors and proteins. His research objectives encompass design and synthesis strategies that prioritize optimizing radioligand properties, including binding affinity, selectivity, and brain penetrance, to enhance efficacy in CNS imaging studies.

In tandem with design efforts, Sangram’s research delves into meticulous in vitro evaluation, where radioligand-receptor interactions are scrutinized through rigorous binding studies. By assessing parameters such as affinity, selectivity, and metabolic stability, Sangram aims to anticipate radioligands' in vivo behavior accurately, laying a robust foundation for subsequent optimization and translation endeavors.

The crux of Sangram’s research lies in conducting sophisticated in vivo studies utilizing small animal PET imaging techniques to unravel essential parameters of radioligands within the CNS. These studies aim to elucidate brain penetrance, distribution patterns, and specific binding attributes within live animal models, providing comprehensive insights into radiotracer behavior post-administration. Through the strategic integration of design, in vitro evaluation, and in vivo studies, Sangram Nag’s research plan navigates the complex landscape of novel PET radioligand development for CNS imaging, contributing significantly to the advancement of precision diagnostics and therapeutic interventions in neurological disorders.